Non-profit research organisation Biohub has released what it claims is an AI-powered "world model" of protein biology that ...
After its advisory committee voted against AstraZeneca's camizestrant as a treatment for breast cancer in April, the FDA has ...
Roche has introduced what it says is the first comprehensive panel of certified algorithms to help manage people living with ...
A $140 million fund has been launched by Coefficient Giving, a health-focused philanthropic organisation, to fund R&D into ...
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Kris Kaneta, chief product officer at Norstella, which is helping life sciences companies speed up development with instant ...
Digital medicine specialist Newel Health has formed an alliance with packaging group Gerresheimer to help pharma companies ...
Gilead Sciences' Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate anitocabtagene autoleucel (anito-cel) which is being prepared for a filing and potential ...
The UK life sciences raised £1.23 billion ($1.65 billion) in venture capital investment in the first half of 2025, putting it on course to at least match the 2024 total for the full year. That's the ...
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically cleared for folate receptor-alpha (FRα) positive, platinum-resistant ovarian ...
Bayer chief executive Bill Anderson has said that newer product launches have offset the decline in sales of anticoagulant Xarelto in the first quarter, and he is confident that this will continue ...
Could there be a third big pharma acquisition this week? MSD is rumoured to be in talks to buy Revolution Medicines in a deal that could be worth up to $32 billion. The chatter – first reported by the ...
The only available treatment for a patient with coeliac disease is a strict gluten-free diet, which is often not enough on its own to curb symptoms. Now, the FDA has said it will carry out a speedy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results